Control group:Immunization with inactivated COVID-19 vaccine(Vero cell) before participating in the study

3 trials

Sponsors

China National Biotec Group Co.Ltd

Conditions

Novel coronavirus Pneumonia (COVID-19)

Phase 4

Evaluation of immunogenicity and safety of novel Coronavirus inactivated vaccine (Vero cells) among patients with autoimmune diseases

Active, not recruitingChiCTR2100054384

China National Biotec Group Co.LtdNovel coronavirus Pneumonia (COVID-19)

Start: 2022-02-15Updated: 2022-11-20

Evaluation of immunogenicity and safety of novel Coronavirus inactivated vaccine (Vero cells) among patients with malignant tumor

Active, not recruitingChiCTR2100054398

China National Biotec Group Co.LtdNovel coronavirus Pneumonia (COVID-19)

Start: 2022-02-14Updated: 2022-11-20

Evaluation of immunogenicity and safety of novel Coronavirus inactivated vaccine (Vero cells) among patients with vital organ damage

Active, not recruitingChiCTR2100054400

China National Biotec Group Co.LtdNovel coronavirus Pneumonia (COVID-19)

Start: 2022-02-15Updated: 2022-11-20